stockrowBioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
Follow BCRX
Alert me
BioCryst Pharmaceuticals, Inc. (BCRX) EV/FCF
As of 5 November 2026, BioCryst Pharmaceuticals, Inc. (BCRX) trades at a EV/FCF of 6.6×. Over the past ten years it has ranged from −123× (July 2015) to 150× (July 2025); the current reading is higher than 91% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 5.3× | — |
| FY2024 | −38.8× | — |
| FY2023 | −16.6× | — |
| FY2022 | −15.0× | — |
| FY2021 | −17.7× | — |
| FY2020 | −9.0× | — |
| FY2019 | −3.5× | — |
| FY2018 | −8.2× | — |
| FY2017 | −8.9× | — |
| FY2016 | −7.5× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 7.1× | (11.93%) |
| Jun 2026 | 8.1× | (13.90%) |
| Mar 2026 | 9.4× | 76.46% |
| Dec 2025 | 5.3× | (87.57%) |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ALVO Alvotech compare | −11.9× |
| RGC Regencell Bioscience Holdings Limited compare | 0.9× |
| BCRX BioCryst Pharmaceuticals, Inc. | 6.6× |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 7.5× |
| ANIP ANI Pharmaceuticals, Inc. compare | 8.2× |
| TRLV Trulieve Cannabis Corp. compare | 12.0× |
| PBH Prestige Consumer Healthcare Inc. compare | 19.2× |
| PRGO Perrigo Company plc compare | 28.6× |
| XERS Xeris Biopharma Holdings, Inc. compare | 33.9× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on BCRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement